Upgrade to SI Premium - Free Trial

Form 3 Evogene Ltd. For: Mar 18 Filed by: ELDAD YARON

March 18, 2026 8:09 AM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
ELDAD YARON
(Last) (First) (Middle)
30 HAIRIT ST.
(Street)
MAALE ADUMIM 9853815
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026 		3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares (1) 4,100
D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy ordinary shares) (2) 03/30/2032 Ordinary shares 15,000 12.584 D
Stock Option (right to buy ordinary shares) (3) 11/20/2034 Ordinary shares 60,000 2.3 D
Explanation of Responses:
1. The ordinary shares reported in this row consist of 4,100 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person and that commenced vesting on April 1, 2023 and vest and become exercisable on an equal, quarterly basis (6.25% per quarter) over a four-year period such that they will be fully vested on the four-year anniversary of the grant date.
2. The options reported in this row vest and become exercisable over a period of four years from the March 30, 2022 vesting commencement date: 25% of the options vested upon the one-year anniversary of the vesting commencement date, and the remaining options vest on an equal quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the vesting commencement date.
3. The options reported in this row vest and become exercisable over a period of four years from the November 20, 2024 vesting commencement date, on an equal, quarterly basis (6.25% per quarter), such that they will be fully vested on the four-year anniversary of the grant date.
Remarks:
Exhibit 24.1 - Power of Attorney.
/s/ Nitsan Deutsch, attorney-in-fact 03/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

EXHIBIT 24.1

Categories

SEC Filings